Elevation Oncology Inc
Change company Symbol lookup
Select an option...
ELEV Elevation Oncology Inc
FRZA Forza X1 Inc
SIEN Sientra Inc
PMGM Priveterra Acquisition Corp
NVFY Nova LifeStyle Inc
GGIFF Garibaldi Resources Corp
MIGI Mawson Infrastructure Group Inc
GTIM Good Times Restaurants Inc
BENF Avalon Acquisition Inc
SOS Sos Ltd
Go

Health Care : Biotechnology |
Company profile

Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 (SYSA1801 or CPO102), is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Claudin 18.2 is expressed across several solid tumor types, including many gastrointestinal cancers such as gastric, gastroesophageal junction and pancreatic cancer. Claudin 18.2 is also expressed in ovarian cancer, non-small cell lung cancer (NSCLC) and other solid tumors. The Company is exploring opportunities through new or existing partnerships and business development opportunities to expand its novel oncology pipeline.

Price
Delayed
$1.74
Day's Change
-1.09 (-38.48%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.07
Day's Low
1.50
Volume
(Heavy Day)

Today's volume of 5,935,153 shares is on pace to be much greater than ELEV's 10-day average volume of 8,118,558 shares.

5,935,153

Meta Platforms Inc. Stock Underperforms Friday When Compared To Competitors

4:31 pm ET March 17, 2023 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Meta Platforms Inc. (META) slid 4.55% to $195.61 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index falling 0.74% to 11,630.51 and Dow Jones Industrial Average falling 1.19% to 31,861.98. The stock's fall snapped a four-day winning streak. Meta Platforms Inc. closed $41.25 below its 52-week high ($236.86), which the company achieved on April 5th.

The stock underperformed when compared to some of its competitors Friday, as Apple Inc. (AAPL) fell 0.55% to $155.00, Microsoft Corp. (MSFT) rose 1.17% to $279.43, and Alphabet Inc. Cl C (GOOGL) rose 1.38% to $102.46. Trading volume (49.7 M) eclipsed its 50-day average volume of 33.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled March 17, 2023.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

	

(END) Dow Jones Newswires

March 17, 2023 16:31 ET (20:31 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.